newsfilter
← Latest News
PR Newswire·

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

If approved, XTANDI would become the first and only novel hormone therapy approved in this earlier type of prostate cancer NEW YORK and TOKYO, Aug. 23, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc.